Consistent with our results, analysis of multiple publicly available breast cancer mRNA expression datasets also showed significantly higher LIMK2 mRNA expression in TNBC (ERBB2/ER/PR negative) compared to breast cancer with other biomarker status (Fig. S1d–i)21–26. This evidence concerns the gene ERBB2 and breast carcinoma.